309 related articles for article (PubMed ID: 32664894)
21. Response to cyclosporine A in a patient with pure red cell aplasia due to antierythropoietin-alpha antibodies.
Fraer M; Campbell A; Sawaya BP
Semin Dial; 2006; 19(3):251-4. PubMed ID: 16689978
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin-induced, antibody-mediated pure red cell aplasia.
Rossert J;
Eur J Clin Invest; 2005 Dec; 35 Suppl 3():95-9. PubMed ID: 16281965
[TBL] [Abstract][Full Text] [Related]
23. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.
Hashimoto K; Harada M; Kamijo Y
Int J Hematol; 2016 Oct; 104(4):502-5. PubMed ID: 27338269
[TBL] [Abstract][Full Text] [Related]
24. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
25. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.
Katagiri D; Shibata M; Katsuki T; Masumoto S; Katsuma A; Minami E; Hoshino T; Inoue T; Tada M; Hinoshita F
Clin Exp Nephrol; 2010 Oct; 14(5):501-5. PubMed ID: 20652821
[TBL] [Abstract][Full Text] [Related]
26. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure.
Shinohara K; Mitani N; Miyazaki M; Sakuragi S; Matsuda K; Ogawara S; Saito T; Kaneoka H; Ooji T
Am J Hematol; 2005 Jan; 78(1):15-20. PubMed ID: 15609276
[TBL] [Abstract][Full Text] [Related]
27. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
28. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
30. Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia.
Praditpornsilpa K; Tiranathanakul K; Jootar S; Tungsanga K; Eiam-Ong S
Clin Nephrol; 2014 May; 81(5):355-8. PubMed ID: 23110772
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine.
Hirai K; Ookawara S; Miyazawa H; Ito K; Ueda Y; Kaku Y; Hoshino T; Kimura SI; Yoshida I; Kakuta S; Morishita Y; Tabei K
CEN Case Rep; 2016 May; 5(1):78-82. PubMed ID: 28509169
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
Kacarska-Fotevska II; Volckova N; Ilievska K; Donev D
Med Arch; 2020 Apr; 74(2):109-114. PubMed ID: 32577051
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
Carson KR; Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
[TBL] [Abstract][Full Text] [Related]
34. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone.
Andrade J; Taylor PA; Love JM; Levin A
Nephrol Dial Transplant; 2005 Nov; 20(11):2548-51. PubMed ID: 16046510
[TBL] [Abstract][Full Text] [Related]
35. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
Macdougall IC
Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
[TBL] [Abstract][Full Text] [Related]
36. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
[TBL] [Abstract][Full Text] [Related]
37. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.
Woodburn KW; Fan Q; Winslow S; Chen MJ; Mortensen RB; Casadevall N; Stead RB; Schatz PJ
Exp Hematol; 2007 Aug; 35(8):1201-8. PubMed ID: 17662888
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
[TBL] [Abstract][Full Text] [Related]
39. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
40. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
